期刊文献+

主动外排系统介导细菌对替加环素产生耐药的机制研究进展 被引量:7

原文传递
导出
摘要 目的:综述国内外在主动外排系统介导细菌产生替加环素耐药机制方面的最新研究进展。方法:通过查阅美国国立医学图书馆和中国知网学术期刊全文数据库,以"替加环素""耐药"等为关键词,使用布尔逻辑算符"and"进行检索,收集从2004-2013年以来有关主动外排系统介导细菌产生替加环素耐药机制的研究文献进行归纳。结果:主动外排系统在细菌产生替加环素耐药的机制中占重要地位,参与耐药形成的外排泵家族包括耐药节结化细胞分化(RND)家族、多药及毒性化合物外排(MATE)家族与主要易化子(MFS)超家族。在医院常见的革兰阴性耐药菌如大肠埃希菌、鲍曼不动杆菌、铜绿假单胞菌中,RND家族外排泵是介导上述细菌产生替加环素耐药性的主要原因;在革兰阳性致病菌中,MATE家族参与替加环素耐药性的产生;而主要MFS超家族中的TetA外排泵仅介导沙门氏菌对替加环素的耐药性。结论:细菌对替加环素耐药的现象有增多趋势,临床上应慎重、合理地使用替加环素;主动外排系统在细菌产生替加环素耐药的机制中占关键地位,进一步研发外排泵抑制剂,可遏制细菌对替加环素耐药的发生。
出处 《中国药房》 CAS CSCD 2014年第21期2010-2013,共4页 China Pharmacy
  • 相关文献

参考文献28

  • 1Putman M,Van Veen HW,Konings WN.Molecular properties of bacterial multidrug transporters[J].Microbiol Mol Biol Rev,2000,64(4):672.
  • 2Piddock LJ.Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria[J].Clin Microbiol Rev,2006,19(2):382.
  • 3Seeger MA,Schiefner A,Eicher T,et al.Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism[J].Science,2006,313(5 791):1 295.
  • 4Rajendran R,Quinn RF,Murray C,et al.Efflux pumps may play a role in tigecycline resistance in Burkholderia species[J].Int J Antimicrob Agents,2010,36(2):151.
  • 5Veleba M,De Majumdar S,Hornsey M,et al.Genetic characterization of tigecycline resistance in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes[J].J Antimicrob Chemother,2013,68(5):1 011.
  • 6Hornsey M,Ellington MJ,Doumith M,et al.Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment[J].Int J Antimicrob Agents,2010,35(5):478.
  • 7Rosenblum R,Khan E,Gonzalez G,et al.Genetic regulation of the ramA locus and its expression in clinical isolates of Klebsiella pneumoniae[J].Int J Antimicrob Agents,2011,38(1):39.
  • 8Horiyama T,Nikaido E,Yamaguchi A,et al.Roles of salmonella multidrug efflux pumps in tigecycline resistance[J].J Antimicrob Chemother,2011,66(1):105.
  • 9Hentschke M,Wolters M,Sobottka I,et al.ramR mutations in clinical isolates of klebsiella pneumoniae with reduced susceptibility to tigecycline[J].Antimicrob Agents Chemother,2010,54(6):2 720.
  • 10Hirata T,Saito A,Nishino K,et al.Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline(GAR-936)[J].Antimicrob Agents Chemother,2004,48(6):2 179.

同被引文献70

  • 1Wyeth Pharmaceuticals Inc. Philadelphia P. Lable of TYGACIL (tigecycline) for intravenous use[EB/OL], http: ffwaccessdatafd- agov/drugsatfda _ docs/label/2013 / 021821 -sO26s031 lblpdf , 2013- 09/2015 -07 -06.
  • 2Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug- resistant Gram-negative pathogens: current and emerging therapeutic approaches [ J ]. Expert Opinion on Pharmacotherapy, 2014, 15 (10) : 1351-1370.
  • 3Giamarellou H. Muhidrug-resistant Gram-negative bacteria: how to treat and for how long[ J]. International Journal of Antimicrobial A- gents,2010,36( Suppl 2) : $50-$54.
  • 4Hanberger H, Giske CG, Giamarellou H. When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock[ J]. Current Infectious Disease Reports,2011,13 (5) : 416-425.
  • 5Poulakou G, Kontopidou FV, Paramythiotou E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens [J]. Journal of Infection, 2009,58 (4) : 273 -284.
  • 6Morfin-Otero R, Dowzieky MJ. Changes in MIC within a global collec- tion of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009 [ J]. Clinical Thera- peutics,2012,34 ( 1 ) : 101-112.
  • 7Kanj SS, Whitelaw A, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011 [ J]. International Journal of Antimicrobial Agents, 2014,43 ( 2 ) : 170-178.
  • 8Sun JR,Perng CL,Lin JC,et al. AdeRS combination codes differenti- ate the response to efflux pump inhibitors in tigecycline-resistant iso- lates of extensively drug-resistant Aeinetobaeter baumannii [ J ]. Eu- ropean Journal of Clinical Microbiology & Infectious Diseases : Offi- cial Publication of the European Society of Clinical Microbiology, 2014,33 (12) : 2141-2147.
  • 9Pallotto C, Fiorio M, D~Avolio A ,et al. Cerebrospinal fluid penetration of tigecycline[J]. Scandinavian journal of Infectious Diseases,2014, 46( 1 ) :69-72.
  • 10Ray L, Levasseur K, Nicolau DP,et al. Cerebral spinal fluid penetra- tion of tigecycline in a patient with Acinetobacter baumannii cerebri- tis[J]. Annals of Pharmacotherapy,2010,44 ( 3 ) :582-586.

引证文献7

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部